A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors

Mise à jour : Il y a 4 ans
Référence : NCT01731925

Femme et Homme

Extrait

Sunitinib may provide an opportunity for a novel therapeutic strategy for the treatment of subjects with neuroendocrine tumors.


Critère d'inclusion

  • Carcinoid Tumors

Liens